Filing Overview
Alpha Tau Medical Ltd. furnished a Form 6-K for September 2023 on September 14, 2023. The report references a press release announcing treatment of the first patient with advanced inoperable pancreatic cancer at Israel’s Hadassah Medical Center.
Business Context and Reporting Period
The filing concerns Alpha Tau’s clinical development activities and treatment using its Alpha DaRT technology. The reported event occurred on September 14, 2023. The filing is furnished under Form 6-K and is not deemed filed for Section 18 liability purposes or incorporated by reference unless expressly stated.
Financial and Operating Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, or other quantitative financial metrics.
Material Changes and Developments
- The company reported treating its first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel.
- The underlying press release is identified as Exhibit 99.1, but its substantive text is not included in the provided filing content.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide financial guidance, broader outlook commentary, specific risks, contingencies, or details regarding the treatment outcome. Any clinical, regulatory, or development implications should be verified against the full Exhibit 99.1 press release and related disclosures.
Investor Verification Items
- Review Exhibit 99.1 for the treatment protocol, clinical-trial design, patient status, and management commentary.
- Verify the applicable regulatory approvals, trial endpoints, enrollment plans, and expected development timeline.
- Assess the company’s latest financial statements for cash runway, funding requirements, operating losses, and liquidity.
- Confirm whether subsequent filings report additional pancreatic cancer patients, safety findings, efficacy data, or changes to the clinical program.